Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Mar 28, 2024
- Accession no.
- 0001415889-24-009364
- Filed
- Mar 28, 2024
- Trade date
- Mar 27, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $309.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2024 | Common Stock | MOption exerciseAcquired | +11,068 | $10.61 | +$117,431.48 | 12,359 | Direct | |
| Mar 27, 2024 | Common Stock | SSaleDisposed | −11,068 | $27.97 | −$309,571.96 | 1,291 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 27, 2024 | Common Stock | MOption exerciseDisposed | −11,068 | $0.00 | $0 | 29,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.